Horizon Therapeutics PLC (DELISTED) (HZNP:DL)
116.30
0.00 (0.00%)
USD |
NASDAQ |
Oct 09, 16:00
Price Chart
Key Stats
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4815 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others. |
| URL | https://www.horizontherapeutics.com |
| Investor Relations URL | https://ir.horizontherapeutics.com |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 02, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others. |
| URL | https://www.horizontherapeutics.com |
| Investor Relations URL | https://ir.horizontherapeutics.com |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 02, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |